Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Qiagen N.V. Common Shares (NY:QGEN)

48.02 -0.84 (-1.71%)
Streaming Delayed Price Updated: 3:51 PM EDT, Aug 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Qiagen N.V. Common Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
DoorDash To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday
 
Via Benzinga
QIAGEN exceeds outlook for Q2 2025 with solid growth and improved profitability
From QIAGEN N.V.
Via Business Wire
Earnings Scheduled For August 5, 2025
 
Via Benzinga
A Look at Qiagen's Upcoming Earnings Report
 
Via Benzinga
Earnings Scheduled For May 7, 2025
 
Via Benzinga
QIAGEN Expands NGS Portfolio with Launch of QIAseq xHYB Long Read Panels
From QIAGEN N.V.
Via Business Wire
QIAGEN N.V. (NYSE:QGEN) - A Strong Technical Setup for Breakout Investors
QIAGEN N.V. (NYSE:QGEN) shows strong technicals and a high-quality breakout setup, making it a candidate for momentum traders. The stock trades near 52-week highs with clear support and resistance... 
Via Chartmill
QIAGEN N.V. to Release Results for Q2 2025 and Hold Webcast
From QIAGEN N.V.
Via Business Wire
QIAGEN Announces Election of Stephen Rusckowski as Chairman of Supervisory Board
From QIAGEN N.V..
Via Business Wire
QIAGEN N.V. (NYSE:QGEN) – A Quality Stock Worth Considering
QIAGEN N.V. (NYSE:QGEN) is a quality stock with strong revenue growth, high ROIC, and solid cash flow conversion, making it a candidate for long-term investors. 
Via Chartmill
QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership
From QIAGEN N.V.
Via Business Wire
Retail Investors Flock To Incyte As Drug Data, Qiagen Deal Fuel Optimism
Stifel also upgraded the stock to ‘Buy’ with a $107 price target. 
Via Stocktwits
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
From QIAGEN N.V.
Via Business Wire
QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships
From QIAGEN N.V.
Via Business Wire
QIAGEN N.V. (NYSE:QGEN) – A Quality Stock with Strong Fundamentals
QIAGEN N.V. (NYSE:QGEN) is a quality stock with strong revenue growth, high ROIC, and solid financial health, making it a candidate for long-term investors. 
Via Chartmill
QIAGEN expands digital PCR oncology research portfolio through partnership with ID Solutions
From QIAGEN N.V.
Via Business Wire
QIAGEN enhances leading clinical genomics portfolio with acquisition of Genoox AI-powered software
From QIAGEN N.V.
Via Business Wire
QIAGEN announces plans for transition in leadership of Supervisory Board
From QIAGEN N.V.
Via Business Wire
QIAGEN delivers solid Q1 2025 results exceeding outlook; will seek shareholder approval to initiate a dividend and new $500 mn repurchase
From QIAGEN N.V.
Via Business Wire
QIAGEN to Propose Initiation of Annual Cash Dividend for Shareholder Approval at Annual General Meeting
From QIAGEN N.V.
Via Business Wire
QIAGEN Expands Its Digital PCR Portfolio With New Lentivirus Solutions to Strengthen Cell and Gene Therapy Quality Control
From QIAGEN N.V.
Via Business Wire
QIAGEN Advances Cancer Genomic Profiling With New Products and Partnership Updates at AACR Annual Meeting 2025
From QIAGEN N.V.
Via Business Wire
QIAGEN Advancing Plans to Launch Three New Sample Preparation Instruments by 2026 to Improve Lab Automation
From QIAGEN N.V.
Via Business Wire
QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast
From QIAGEN N.V.
Via Business Wire
Qiagen Shares Rise Premarket As Preliminary Q1 Results, Hikes FY25 EPS Guidance
Qiagen (QGEN) shares up premarket after disclosing strong preliminary Q1 2025 results and raising full-year EPS outlook. Stock price up 3.06%. 
Via Benzinga
QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS Outlook
From QIAGEN N.V.
Via Business Wire
QIAGEN N.V.: QIAGEN Announces Strong Preliminary Q1 2025 Results and Updates Full-Year 2025 Adjusted Earnings per Share Outlook
Via ACCESS Newswire
QIAGEN Launches QIAprep&amp Plasmodium Kit to Strengthen Malaria Research and Surveillance Efforts
From QIAGEN N.V.
Via Business Wire
QIAGEN Announces Form 20-F Annual Report Filing for 2024 Results
From QIAGEN N.V.
Via Business Wire
QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio
From QIAGEN N.V.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.